<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Dasatinib</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01254</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Dasatinib is an oral dual <span class="caps">BCR</span>/<span class="caps">ABL</span> and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (<span class="caps">CML</span>). The main targets of Dasatinib, are <span class="caps">BCRABL</span>, <span class="caps">SRC</span>, Ephrins and <span class="caps">GFR</span>.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01254/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01254/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01254.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01254.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01254.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01254.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01254.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01254">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Sprycel</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>302962-49-8</td></tr><tr><th>Weight</th><td>Average: 488.006<br>Monoisotopic: 487.155721508</td></tr><tr><th>Chemical Formula</th><td>C<sub>22</sub>H<sub>26</sub>ClN<sub>7</sub>O<sub>2</sub>S</td></tr><tr><th>InChI Key</th><td>ZBNZXTGUTAYRHI-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Anilides</td></tr><tr><th>Direct parent</th><td>Anilides</td></tr><tr><th>Alternative parents</th><td>Thiazolecarboxamides; Toluenes; Aminopyrimidines and Derivatives; Chlorobenzenes; 2,5-disubstituted Thiazoles; Diazinanes; Aryl Chlorides; Aminothiazoles; Piperazines; Tertiary Amines; Secondary Carboxylic Acid Amides; Primary Alcohols; Carboxylic Acids; Enolates; Secondary Amines; Polyamines; Organochlorides</td></tr><tr><th>Substituents</th><td>thiazolecarboxylic acid or derivative; thiazolecarboxamide; 2,5-disubstituted 1,3-thiazole; aminopyrimidine; toluene; chlorobenzene; aryl halide; piperazine; aryl chloride; 1,3-thiazolamine; pyrimidine; 1,4-diazinane; thiazole; azole; secondary carboxylic acid amide; tertiary amine; carboxamide group; polyamine; primary alcohol; enolate; carboxylic acid derivative; carboxylic acid; secondary amine; organohalogen; organochloride; amine; organonitrogen compound; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the anilides. These are organic heterocyclic compounds derived from&#160;oxoacids&#160;RkE(=O)l(OH)m&#160;(l&#160;not 0) by replacing an&#160;OH&#160;group by the&#160;NHPh group or derivative formed by ring substitution.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.</td></tr><tr><th>Pharmacodynamics</th><td>Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor</td></tr><tr><th>Mechanism of action</th><td>Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFR&#946;. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression. </td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>2505 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>96%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Dasatinib is extensively metabolized in humans, primarily by the cytochrome P450 enzyme 3A4</p></td></tr><tr><th>Route of elimination</th><td>Dasatinib is extensively metabolized in humans, primarily by the cytochrome P450 enzyme 3A4.  Elimination is primarily via the feces.</td></tr><tr><th>Half life</th><td>The overall mean terminal half-life of dasatinib is 3-5 hours.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Acute overdose in animals was associated with cardiotoxicity.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9852</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.507</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5638</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6562</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5371</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.5425</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7288</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7061</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8152</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5704</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5612</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.8008</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8358</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.574</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.7295</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.8343</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7185
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7308
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9863
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4772 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8538
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.718
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Bristol myers squibb co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li>E.R. Squibb and Sons LLC</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Dasatinib, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. 

It is recommended to avoid this combination if possible. If concurrent therapy cannot be avoided it is recommended to increase the dose of dasitinib and monitor for efficacy and toxicity.  </td></tr><tr><td><a href="/drugs/DB00338">Omeprazole</a></td><td>Omeprazole may decrease the serum level of dasatinib.</td></tr><tr><td><a href="/drugs/DB00213">Pantoprazole</a></td><td>Pantoprazole may decrease the serum level of dasatinib.</td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>Phenobarbital may decrease the serum level and efficacy of dasatinib.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Phenytoin may decrease the serum level and efficacy of dasatinib.</td></tr><tr><td><a href="/drugs/DB01129">Rabeprazole</a></td><td>Rabeprazole may decrease the serum level of dasatinib.</td></tr><tr><td><a href="/drugs/DB00863">Ranitidine</a></td><td>Ranitidine may decrease the serum level of dasatinib.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the serum level and efficacy of dasatinib.</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Dasatinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Dasatinib if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. </td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of dasatinib by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dasatinib if voriconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB02546">Vorinostat</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>